Reality Check on Acute Myeloid Leukemia
Market access for acute myeloid leukemia treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 65% and 80% of the lives under commercial and Medicare formularies are covered with utilization management restrictions
- Class Trends: In June 2019, Daiichi Sankyo Company, Ltd. said that the FDA had issued a complete response letter (CRL) for its new drug application (NDA) for quizartinib for the treatment of adults with R/R FLT3-internal tandem duplications acute myeloid leukemia
- Key Findings: An abundance of policies exists on the pharmacy side, particularly for the newer targeted therapies. Vyxeos is a combination of generics that are already on the market in a liposomal injection. It will likely have to step through the generic agents on the market before being considered for reimbursement
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.